{"entity":{"id":"nct05061550","kind":"trial","name":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Durvalumab, Oleclumab, Monalizumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.","summary":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05061550 by AstraZeneca, with 630 participants planned, started 2022-04-14 and due to reach its primary completion in 2030-05-28. Interventions recorded: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05061550","url":"https://clinicaltrials.gov/study/NCT05061550"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab","oleclumab","monalizumab","datopotamab-deruxtecan","carboplatin","cisplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05061550","phase":"2","setting":"A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)","sponsor":"AstraZeneca","enrolled":630,"outcomes":[]},"route":"/trials/nct05061550/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"monalizumab","kind":"drug","name":"Monalizumab","route":"/drugs/monalizumab/"},{"id":"oleclumab","kind":"drug","name":"Oleclumab","route":"/drugs/oleclumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}